Compass Therapeutics (CMPX) Fundamental Analysis: Revenue, Earnings & Valuation

7.08 / 10

Outperform

Financial analysis yields satisfactory rating (7.1/10). Positive contributors: Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, however risks emerge in Quick ratio and Asset-MV. Concluding evaluation: promising.

Analysis Checks(6/10)

Revenue-MV

Value-0.18

Score3/3

Weight32.10%

1M Return8.82%

Total operating revenue (YoY growth rate %)

Value142.02

Score2/3

Weight0.96%

1M Return0.35%

Quick ratio

Value2.34

Score1/3

Weight-2.36%

1M Return-0.93%

PB-ROE

Value2.32

Score3/3

Weight51.84%

1M Return14.45%

Income tax / Total profit (%)

Value19.90

Score0/3

Weight-3.70%

1M Return-1.49%

Long-term debt to working capital ratio (%)

Value0.05

Score3/3

Weight4.81%

1M Return1.83%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-2.02%

1M Return-0.77%

Cost of sales ratio (%)

Value71.87

Score2/3

Weight-1.53%

1M Return-0.61%

Asset-MV

Value-0.72

Score1/3

Weight22.52%

1M Return6.94%

Current ratio

Value15.02

Score1/3

Weight-2.62%

1M Return-1.01%

Is CMPX fundamentally strong?

CMPX scores 7.08/10 on fundamentals and holds a Discounted valuation at present. Backed by its -41.29% ROE, 0.00% net margin, -14.52 P/E ratio, 4.91 P/B ratio, and -16.67% earnings growth, these metrics solidify its Outperform investment rating.